WOODCLIFF LAKE, N.J., April 21 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) ("Par") today announced it has entered into a settlement agreement with Reliant Pharmaceuticals, Inc.

LONDON and PHILADELPHIA, Dec. 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that it had completed the acquisition of Reliant Pharmaceuticals. This follows the US Federal Trade Commission's early termination of the waiting period required by US antitrust law.

Privately-owned specialty pharma company Reliant Pharmaceuticals holds the US license to Lovaza, a dyslipidemia therapy which is thought to have provided the primary motivation for GlaxoSmithKline's $1.65 billion takeover offer.

GlaxoSmithKline has reached an agreement with Reliant Pharmaceuticals to acquire the company for $1.65 billion in cash.

By GIDEON SPANIER DRUGS giant GlaxoSmithKline today moved to shore up some of the hundreds of millions of dollars it lost in sales this summer because of the Avandia diabetes drug scare, by paying Pounds 800 million for heart medicine firm Reliant Pharmaceuticals.